<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               1 INDICATIONS AND USAGE<BR>               <BR>               <BR>                  <BR>                     <BR>                        <BR>                           Vectibix is an epidermal growth factor receptor antagonist indicated as a single agent for the treatment of metastatic colorectal carcinoma (mCRC) with disease progression on or following fluoropyrimidine, oxaliplatin, and irinotecan chemotherapy regimens.  Approval is based on progression-free survival; no data demonstrate an improvement in disease-related symptoms or increased survival with Vectibix. (1.1)<BR><BR>                           Limitation of Use: Vectibix is not indicated for the treatment of patients with KRAS mutation-positive mCRC or for whom KRAS mCRC status is unknown. (1.2, 5.3, 12.1, 14.3)<BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     1.1  Metastatic Colorectal Cancer<BR>                     <BR>                        Vectibix is indicated as a single agent for the treatment of epidermal growth factor receptor (EGFR)-expressing, metastatic colorectal carcinoma (mCRC) with disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens [see Clinical Studies (14.1)].<BR>                        The effectiveness of Vectibix as a single agent for the treatment of EGFR-expressing, metastatic colorectal carcinoma is based on progression-free survival [see Clinical Studies (14.1)].  Currently, no data demonstrate an improvement in disease-related symptoms or increased survival with Vectibix.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     1.2 Limitation of Use<BR>                     <BR>                        <BR>                           Vectibix is not indicated for the treatment of patients with KRAS mutation-positive mCRC or for whom KRAS mCRC status is unknown.  Retrospective subset analyses of metastatic colorectal cancer trials have not shown a treatment benefit for Vectibix in patients whose tumors had KRAS mutations in codon 12 or 13 [see Warnings and Precautions (5.3), Clinical Pharmacology (12.1), and Clinical Studies (14.3)].<BR>                        <BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>